# Vorinostat in Treating Patients With Kidney Cancer

> **NCT00278395** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 14 (actual)

## Conditions studied

- Recurrent Renal Cell Carcinoma
- Stage IV Renal Cell Cancer

## Interventions

- **DRUG:** Vorinostat

## Key facts

- **NCT ID:** NCT00278395
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2017-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00278395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00278395, "Vorinostat in Treating Patients With Kidney Cancer". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00278395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*